全脑放疗或立体定向放射外科治疗五个及以上脑转移瘤(WHOBI-STER):一项前瞻性比较研究,评估神经认知结局、日常生活自主水平与生活质量
WHOBI-STER是一项多中心随机对照试验,计划纳入100例(每臂50例)实体瘤脑转移≥5个的患者,随机接受立体定向脑照射(SBI)或全脑照射(WBI),主要终点为神经认知表现、生活质量与日常生活自主性变化,次要终点包括颅内失败时间、总生存、再治疗率、急晚期毒性与KPS变化。
要点
- 拟纳入100例脑转移≥5个、KPS≥70、MoCA≥20/30、Barthel≥90/100的实体瘤患者。
- 试验组为LINAC单等中心非共面弧立体定向脑照射,对照组为全脑照射。
- 主要终点用MoCA与HVLT-R评估神经认知,EORTC QLQ-C15-PAL与QLQ-BN-20评估生活质量,Barthel指数评估自主性。
核心结论
- 作者认为,关于脑照射后神经认知衰退的决定因素是射线对临床健康脑组织的作用还是颅内肿瘤负荷,答案可能来自能同时选择性治疗多个脑转移瘤且减少靶外脑受照剂量的技术进步。
- 作者指出,获得与全脑照射相当的局部控制率仍是根本前提。
研究设计与样本
- 多中心随机对照试验,计划纳入100例(每臂50例)实体瘤脑转移≥5个的患者。
- 入组条件包括年龄≥18岁、KPS≥70、预期生存>3个月、已知原发肿瘤、颅外疾病可控或可控制、基线MoCA评分≥20/30、Barthel日常生活活动评分≥90/100。
- 试验组为LINAC单等中心技术与非共面弧的立体定向脑照射,对照组为全脑照射。
主要发现
- 主要终点为神经认知表现、生活质量与日常生活自主性变化,分别用MoCA评分与霍普金斯词语学习测验修订版、EORTC QLQ-C15-PAL与QLQ-BN-20问卷、Barthel指数评估。
- 次要终点为颅内失败时间、总生存、再治疗率、急性和晚期毒性、KPS变化。
- 两组间至少30%的统计学差异将被视为显著(统计效力80%,显著性水平95%)。
关键数值与推荐
- 主要终点神经认知表现采用MoCA评分与霍普金斯词语学习测验修订版评估。
- 生活质量采用EORTC QLQ-C15-PAL与QLQ-BN-20问卷评估。
- 日常生活自主性采用Barthel指数评估。
- 显著性标准为两组间至少30%的统计学差异(统计效力80%,显著性水平95%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To evaluate neurocognitive performance, daily activity and quality of life (QoL), other than usual oncologic outcomes, among patients with brain metastasis ≥5 (MBM) from solid tumors treated with Stereotactic Brain Irradiation (SBI) or Whole Brain Irradiation (WBI). METHODS: This multicentric randomized controlled trial will involve the enrollment of 100 patients (50 for each arm) with MBM ≥ 5, age ≥ 18 years, Karnofsky Performance Status (KPS) ≥ 70, life expectancy > 3 months, known primary tumor, with controlled or controllable extracranial disease, baseline Montreal Cognitive Assessment (MoCA) score ≥ 20/30, Barthel Activities of Daily Living score ≥ 90/100, to be submitted to SBI by LINAC with monoisocentric technique and non-coplanar arcs (experimental arm) or to WBI (control arm). The primary endpoints are neurocognitive performance, QoL and autonomy in daily-life activities variations, the first one assessed by MoCa Score and Hopkins Verbal Learning Test-Revised, the second one through the EORTC QLQ-C15-PAL and QLQ-BN-20 questionnaires, the third one through the Barthel Index, respectively. The secondary endpoints are time to intracranial failure, overall survival, retreatment rate, acute and late toxicities, changing of KPS. It will be considered significant a statistical difference of at least 30% between the two arms (statistical power of 80% with a significance level of 95%). DISCUSSION: Several studies debate what is the decisive factor accountable for the development of neurocognitive decay among patients undergoing brain irradiation for MBM: radiation effect on clinically healthy brain tissue or intracranial tumor burden? The answer to this question may come from the recent technological advancement that allows, in a context of a significant time saving, improved patient comfort and minimizing radiation dose to off-target brain, a selective treatment of MBM simultaneously, otherwise attackable only by WBI. The achievement of a local control rate comparable to that obtained with WBI remains the fundamental prerequisite. TRIAL REGISTRATION: NCT number: NCT04891471.
引用
- Ferini G, Viola A, Valenti V, et al. Whole Brain Irradiation or Stereotactic RadioSurgery for five or more brain metastases (WHOBI-STER): A prospective comparative study of neurocognitive outcomes, level of autonomy in daily activities and quality of life. Clin Transl Radiat Oncol. 2021. PMID: 34926839. doi:10.1016/j.ctro.2021.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。